132. Deputy Pádraig O'Sullivan asked the Minister for Health further to Parliamentary Question No. 158 of 22 May 2024, when the HSE executive management team will be in a position to approve or make a decision on the reimbursement application for dostarlimab (jemperli) indicated as monotherapy for the treatment of adult patients with recurrent or advance endometrial cancer; and if he will make a statement on the matter. [25807/24]

Summary

132. Deputy Pádraig O'Sullivan asked the Minister for Health further to Parliamentary Question No. 158 of 22 May 2024, when the HSE executive management team will be in a position to approve or make a decision on the reimbursement application for dostarlimab (jemperli) indicated as monotherapy for the treatment of adult patients with recurrent or advance endometrial cancer; and if he will make a statement on the matter. [25807/24]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 13 June 2024

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.